These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21625960)

  • 1. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.
    Lambracht-Washington D; Qu BX; Fu M; Anderson LD; Stüve O; Eagar TN; Rosenberg RN
    Cell Mol Neurobiol; 2011 Aug; 31(6):867-74. PubMed ID: 21625960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
    Lambracht-Washington D; Qu BX; Fu M; Eagar TN; Stüve O; Rosenberg RN
    JAMA; 2009 Oct; 302(16):1796-802. PubMed ID: 19861672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.
    Lambracht-Washington D; Fu M; Frost P; Rosenberg RN
    Alzheimers Res Ther; 2017 Apr; 9(1):30. PubMed ID: 28441965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer.
    Lambracht-Washington D; Fu M; Wight-Carter M; Riegel M; Rosenberg RN
    J Alzheimers Dis; 2017; 57(1):97-112. PubMed ID: 28222511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active full-length DNA Aβ
    Rosenberg RN; Fu M; Lambracht-Washington D
    Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
    Ghochikyan A; Mkrtichyan M; Petrushina I; Movsesyan N; Karapetyan A; Cribbs DH; Agadjanyan MG
    Vaccine; 2006 Mar; 24(13):2275-82. PubMed ID: 16368167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.
    Lambracht-Washington D; Rosenberg RN
    Neurobiol Aging; 2015 Mar; 36(3):1274-81. PubMed ID: 25725942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the brain transcriptome after DNA Aβ42 trimer immunization in a 3xTg-AD mouse model.
    Lambracht-Washington D; Fu M; Hynan LS; Rosenberg RN
    Neurobiol Dis; 2021 Jan; 148():105221. PubMed ID: 33316368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice.
    Liu S; Shi D; Wang HC; Yu YZ; Xu Q; Sun ZW
    Sci Rep; 2015 Jan; 5():7771. PubMed ID: 25586780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid β 3-10 DNA vaccination suggests a potential new treatment for Alzheimer's disease in BALB/c mice.
    Xing XN; Zhang WG; Sha S; Li Y; Guo R; Wang C; Cao YP
    Chin Med J (Engl); 2011 Sep; 124(17):2636-41. PubMed ID: 22040416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
    Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
    J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
    Town T; Vendrame M; Patel A; Poetter D; DelleDonne A; Mori T; Smeed R; Crawford F; Klein T; Tan J; Mullan M
    J Neuroimmunol; 2002 Nov; 132(1-2):49-59. PubMed ID: 12417433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.
    Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA
    Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Aβ42 immunization via needle-less Jet injection in mice and rabbits as potential immunotherapy for Alzheimer's disease.
    Lambracht-Washington D; Fu M; Wight-Carter M; Riegel M; Hynan LS; Rosenberg RN
    J Neurol Sci; 2023 Mar; 446():120564. PubMed ID: 36731358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.
    Qu BX; Xiang Q; Li L; Johnston SA; Hynan LS; Rosenberg RN
    J Neurol Sci; 2007 Sep; 260(1-2):204-13. PubMed ID: 17574274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.